Citation: D. Sheybani Natasha, Yang Hu. Pediatric ocular nanomedicines:Challenges and opportunities[J]. Chinese Chemical Letters, ;2017, 28(9): 1817-1821. doi: 10.1016/j.cclet.2017.07.022 shu

Pediatric ocular nanomedicines:Challenges and opportunities

D. Sheybani Natasha ^a ,
Yang Hu ^b,c,d,,

a.
Department of Biomedical Engineering, Virginia Commonwealth University, Richmond VA 23284, United States
b.
Department of Chemical & Life Science Engineering, Virginia Commonwealth University, Richmond VA 23219, United States
c.
Department of Pharmaceutics, Virginia Commonwealth University, Richmond VA 23298, United States
d.
Massey Cancer Center, Virginia Commonwealth University, Richmond VA 23298, United States

Corresponding author: Yang Hu, hyang2@vcu.edu
Received Date: 27 April 2017
Revised Date: 20 July 2017
Accepted Date: 21 July 2017
Available Online: 26 September 2017

Figures(4)

The eye is a highly complex, yet readily accessible organ within the human body. As such, the eye is an appealing candidate target for a vast array of drug therapies. Despite advances in ocular drug therapy research, the focus on pediatric ocular drug delivery continues to be highly underrepresented due to the limited number of degenerative ocular diseases with childhood onset. In this review, we explore more deeply the reasons underlying the disparity between ocular therapies available for children and for adults by highlighting diseases that most commonly afflict children (with focus on the anterior eye) and existing prognoses, recent developments in ocular drug delivery systems and nanomedicines for children, and barriers to use for pediatric patients
- Pediatric,
- Ocular drug delivery,
- Nanomedicine,
- Drug administration,
- Compliance
1. [1]
  A. Patel, K. Cholkar, V. Agrahari, et al., World J. Pharmacol. 2(2013) 47-64. doi: 10.5497/wjp.v2.i2.47
2. [2]
  Basmak H., Yildirim N., Topbas S.. Pediatric ophthalmology/eye and disorders, in:Ö. Özdemir (Ed.), Complementary Pediatrics[J]. InTech, Rijeka, 2012:pp. 3-30.
3. [3]
  H.K. Batchelor, J.F. Marriott, Br. J. Clin. Pharmacol. 79(2015) 405-418. doi: 10.1111/bcp.12268
4. [4]
  S. Reimondez-Troitino, N. Csaba, M.J. Alonso, et al., Eur. J. Pharm. Biopharm. 95(2015) 279-293. doi: 10.1016/j.ejpb.2015.02.019
5. [5]
  J.J. Kang-Mieler, C.R. Osswald, W.F. Mieler, Expert Opin. Drug Deliv. 11(2014) 1647-1660. doi: 10.1517/17425247.2014.935338
6. [6]
  E.P. Aponte, N. Diehl, B.G. Mohney, Arch. Ophthalmol. 128(2010) 478-482. doi: 10.1001/archophthalmol.2010.41
7. [7]
  R. Cascella, C. Strafella, C. Germani, et al., Biomed. Res. Int. 2015(2015) 321291.
8. [8]
  J.Y. Yu Chan, B.N. Choy, A.L. Ng, et al., J. Curr. Glaucoma Pract. 9(2015) 92-99. doi: 10.5005/jp-journals-10008
9. [9]
  R.S. Gold, Pediatr. Ann. 40(2011) 95-105. doi: 10.3928/00904481-20110117-09
10. [10]
  D. Bremond-Gignac, H. Nezzar, P.E. Bianchi, et al., Br. J. Ophthalmol. 98(2014) 739-745. doi: 10.1136/bjophthalmol-2013-303888
11. [11]
  K. LaMattina, L. Thompson, Dis.-Mon. 60(2014) 231-238. doi: 10.1016/j.disamonth.2014.03.002
12. [12]
  A. Sheikh, B. Hurwitz, C.P. van Schayck, et al., Cochrane Database Syst. Rev. (2012) CD001211.
13. [13]
  D. Bremond-Gignac, F. Chiambaretta, S. Milazzo, Ophthalmol. Eye Dis. 3(2011) 29-43.
14. [14]
  R.A. Sharma, R. Mather, CMAJ 186(2014) 1090. doi: 10.1503/cmaj.131590
15. [15]
  L. Chen, L. Pi, J. Fang, et al., Acta Ophthalmol. 94(2016) e727-e730. doi: 10.1111/aos.13093
16. [16]
  S.B. Han, H.K. Yang, J.Y. Hyon, et al., Graefe's Arch. Clin. Exp. Ophthalmol. 251(2013) 791-796. doi: 10.1007/s00417-012-2097-2
17. [17]
  M.J. Doughty, D. Fonn, D. Richter, et al., Optom. Vis. Sci. 74(1997) 624-631. doi: 10.1097/00006324-199708000-00023
18. [18]
  A. Hellstrom, L.E. Smith, O. Dammann, Lancet 382(2013) 1445-1457. doi: 10.1016/S0140-6736(13)60178-6
19. [19]
  W.V. Good, R.J. Hardy, V. Dobson, et al., Pediatrics 116(2005) 15-23. doi: 10.1542/peds.2004-1413
20. [20]
  R. Hennig, A. Goepferich, Eur. J. Pharm. Biopharm. 95(2015) 294-306. doi: 10.1016/j.ejpb.2015.02.027
21. [21]
  B. Falsini, A. Chiaretti, G. Barone, et al., Neurorehabil. Neural Repair 25(2011) 512-520. doi: 10.1177/1545968310397201
22. [22]
  R. Gaudana, H.K. Ananthula, A. Parenky, et al., AAPS J. 12(2010) 348-360. doi: 10.1208/s12248-010-9183-3
23. [23]
  C. Dreno, T. Gicquel, M. Harry, et al., Ann. Pharm. Fr. 73(2015) 31-36. doi: 10.1016/j.pharma.2014.06.006
24. [24]
  R.B. Freedman, S.K. Jones, A. Lin, et al., Arch. Ophthalmol. 130(2012) 306-311. doi: 10.1001/archopthalmol.2011.1788
25. [25]
  C. Rangan, G. Everson, F.L. Cantrell, Pediatr. Emerg. Care 24(2008) 167-169. doi: 10.1097/PEC.0b013e3181668aee
26. [26]
  E.J. Campos, A. Campos, J. Martins, et al., Nanomedicine 13(2017) 2101-2113. doi: 10.1016/j.nano.2017.04.008
27. [27]
  M. G. Lancina Ⅲ, H. Yang, Can. J. Chem. (2017), doi: http://dx.doi.org/10.1139/cjc-2017-0193.
28. [28]
  Y. Fan, B. Zhuang, C. Wang, et al., Colloids Surf. B 140(2016) 1-10. doi: 10.1016/j.colsurfb.2015.11.059
29. [29]
  R. Gaudana, J. Jwala, S.H. Boddu, et al., Pharm. Res. 26(2009) 1197-1216. doi: 10.1007/s11095-008-9694-0
30. [30]
  C.A. Holden, P. Tyagi, A. Thakur, et al., Nanomedicine 8(2012) 776-783. doi: 10.1016/j.nano.2011.08.018
31. [31]
  H. Yang, C.T. Leffler, J. Ocul. Pharmacol. Ther. 29(2013) 166-172. doi: 10.1089/jop.2012.0197
32. [32]
  H. Yang, P. Tyagi, R.S. Kadam, et al., ACS Nano 6(2012) 7595-7606. doi: 10.1021/nn301873v
33. [33]
  S.P. Kambhampati, R.M. Kannan, J. Ocul. Pharmacol. Ther. 29(2013) 151-165. doi: 10.1089/jop.2012.0232
34. [34]
  F. Fortinguerra, A. Clavenna, M. Bonati, BMC Pediatr. 12(2012) 8.
1. [1]
  Zhongyu Wang , Lijun Wang , Huaixin Zhao . DNA-based nanosystems to generate reactive oxygen species for nanomedicine. Chinese Chemical Letters, 2024, 35(11): 109637-. doi: 10.1016/j.cclet.2024.109637
2. [2]
  Yating Zheng , Yulan Huang , Jing Luo , Xuqi Peng , Xiran Gui , Gang Liu , Yang Zhang . Supercritical fluid technology: A game-changer for biomacromolecular nanomedicine preparation and biomedical application. Chinese Chemical Letters, 2024, 35(7): 109169-. doi: 10.1016/j.cclet.2023.109169
3. [3]
  Zhi Li , Wenpei Li , Shaoping Jiang , Chuan Hu , Yuanyu Huang , Maxim Shevtsov , Huile Gao , Shaobo Ruan . Legumain-triggered aggregable gold nanoparticles for enhanced intratumoral retention. Chinese Chemical Letters, 2024, 35(7): 109150-. doi: 10.1016/j.cclet.2023.109150
4. [4]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
5. [5]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
6. [6]
  Fengjie Liu , Fansu Meng , Zhenjiang Yang , Huan Wang , Yuehong Ren , Yu Cai , Xingwang Zhang . Exosome-biomimetic nanocarriers for oral drug delivery. Chinese Chemical Letters, 2024, 35(9): 109335-. doi: 10.1016/j.cclet.2023.109335
7. [7]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
8. [8]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
9. [9]
  Zhilong Xie , Guohui Zhang , Ya Meng , Yefei Tong , Jian Deng , Honghui Li , Qingqing Ma , Shisong Han , Wenjun Ni . A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein. Chinese Chemical Letters, 2024, 35(11): 109584-. doi: 10.1016/j.cclet.2024.109584
10. [10]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
11. [11]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
12. [12]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
13. [13]
  Shaoqing Du , Xinyong Liu , Xueping Hu , Peng Zhan . Targeting novel sites represents an effective strategy for combating drug resistance. Chinese Chemical Letters, 2025, 36(1): 110378-. doi: 10.1016/j.cclet.2024.110378
14. [14]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
15. [15]
  Xin Zhang , Junyu Chen , Xiang Pei , Linxin Yang , Liang Wang , Luona Chen , Guangmei Yang , Xibo Pei , Qianbing Wan , Jian Wang . Drug-loading ZIF-8 for modification of microporous bone scaffold to promote vascularized bone regeneration. Chinese Chemical Letters, 2024, 35(6): 108889-. doi: 10.1016/j.cclet.2023.108889
16. [16]
  Liping Zhao , Xixi Guo , Zhimeng Zhang , Xi Lu , Qingxuan Zeng , Tianyun Fan , Xintong Zhang , Fenbei Chen , Mengyi Xu , Min Yuan , Zhenjun Li , Jiandong Jiang , Jing Pang , Xuefu You , Yanxiang Wang , Danqing Song . Novel berberine derivatives as adjuvants in the battle against Acinetobacter baumannii: A promising strategy for combating multi-drug resistance. Chinese Chemical Letters, 2024, 35(10): 109506-. doi: 10.1016/j.cclet.2024.109506
17. [17]
  Fukui Shen , Yuqing Zhang , Guoqing Luan , Kaixue Zhang , Zhenzhen Wang , Yunhao Luo , Yuanyuan Hou , Gang Bai . Revealing drug targets with multimodal bioorthogonal AMPD probes through visual metabolic labeling. Chinese Chemical Letters, 2024, 35(12): 109646-. doi: 10.1016/j.cclet.2024.109646
18. [18]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840
19. [19]
  Jiajia Wang , XinXin Ge , Yajing Xiang , Xiaoliang Qi , Ying Li , Hangbin Xu , Erya Cai , Chaofan Zhang , Yulong Lan , Xiaojing Chen , Yizuo Shi , Zhangping Li , Jianliang Shen . An ionic liquid functionalized sericin hydrogel for drug-resistant bacteria-infected diabetic wound healing. Chinese Chemical Letters, 2025, 36(2): 109819-. doi: 10.1016/j.cclet.2024.109819
20. [20]
  Keyang Li , Yanan Wang , Yatao Xu , Guohua Shi , Sixian Wei , Xue Zhang , Baomei Zhang , Qiang Jia , Huanhua Xu , Liangmin Yu , Jun Wu , Zhiyu He . Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation. Chinese Chemical Letters, 2024, 35(10): 109511-. doi: 10.1016/j.cclet.2024.109511

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(821)
HTML views(30)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142